Last updated on March 2018

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer


Brief description of study

The primary objective of this study is to investigate the effect of 5 mg KHK2375 on progression free survival (PFS) when administered orally at weekly intervals in combination with exemestane in a placebo-controlled, double-blind comparative study in subjects with advanced or recurrent hormone receptor-positive breast cancer. The secondary objectives are to investigate the effect of on overall survival (OS) and the antitumor effect and to evaluate the pharmacokinetics and safety.

Clinical Study Identifier: NCT03291886

Contact Investigators or Research Sites near you

Start Over

Kyowa Hakko Kirin Co., Ltd.

The Cancer Institute Hospital of JFCR
Koto, Japan
  Connect »

Kyowa Hakko Kirin Co., Ltd.

National Cancer Center Hospital
Chuo, Japan
2.56miles
  Connect »

Kyowa Hakko Kirin Co., Ltd.

Toranomon Hospital
Minato, Japan
3.83miles
  Connect »

Kyowa Hakko Kirin Co., Ltd.

Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital
Bunkyo, Japan
4.4miles
  Connect »

Kyowa Hakko Kirin Co., Ltd.

Showa University Hospital
Shinagawa, Japan
6.58miles
  Connect »

Kyowa Hakko Kirin Co., Ltd.

Gunma Cancer Center
Ota, Japan
9.58miles
  Connect »